STOCK TITAN

AIM IMMUNOTECH INC (AIMI) EPS by Year

AIMI

AIM IMMUNOTECH INC lost $8.62 per diluted share in fiscal year 2025. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters AIM IMMUNOTECH INC has filed alongside them.

FY2025 annual
EPS (Diluted) -$8.62
Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

AIMI EPS (Diluted) by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2510-KFY2410-KFY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
EPS (Diluted)-$8.62-$30.92-$0.60-50.0%-$0.40N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A

AIMI EPS (Diluted) by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ1'2610-QQ4'2510-QQ3'2510-QQ2'25Q1'2510-QQ4'2410-KQ3'2410-QQ2'24Q1'24Q4'23Q3'23Q2'23
EPS (Diluted)-$0.69N/A$1.57-$3.68-$0.05N/A-$6.00-$3.00-$0.12-50.0%N/A-$0.16-23.1%-$0.100.0%

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More AIM IMMUNOTECH INC financials

Frequently Asked Questions

What was AIM IMMUNOTECH INC's diluted earnings per share in fiscal year 2025?

AIM IMMUNOTECH INC lost $8.62 per diluted share in fiscal year 2025.

What was AIM IMMUNOTECH INC's diluted earnings per share in the most recent quarter?

AIM IMMUNOTECH INC (AIMI) reported -$0.69 in diluted earnings per share in Q1 2026.

What does diluted earnings per share mean on a financial statement?

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what AIM IMMUNOTECH INC (AIMI) reported on that line in every period on record.